Integrating MCDA and economic evaluation into a rule-based framework for hospital-level health technology assessment [0.03%]
基于规则的医院层面卫生技术评估的多准则决策分析和经济评价集成框架
Gianpaolo Franzoso,Novella Piazzetta,Flavio Cazzador et al.
Gianpaolo Franzoso et al.
Introduction: Health Technology Assessment (HTA) supports evidence-based decision-making, but integrating economic evaluation within Multi-Criteria Decision Analysis (MCDA) remains challenging in hospital-level HTA. This ...
Burden of primary biliary cholangitis on the Italian National Health Service: retrospective analysis from an administrative database [0.03%]
意大利国家卫生保健系统中原发性胆汁性肝硬化疾病负担：来自管理型数据库的回顾性分析
Giulia Ronconi,Letizia Dondi,Nicola Ambrosio et al.
Giulia Ronconi et al.
Introduction: Primary biliary cholangitis (PBC) is a rare, chronic, cholestatic, autoimmune, and disabling liver disease whose treatments are aimed at reducing its progression.The aim was to describe patients with PBC, th...
Algoritmo decisionale per l’interpretazione dell’overall survival immatura in onco-ematologia: sviluppo e applicazione [0.03%]
用于血液肿瘤的不成熟总生存期解读的决策算法：开发和应用
Guido Gini,Laura Gurgoglione,Riccardo Ceccarelli et al.
Guido Gini et al.
Pharmacoeconomic analysis of switch to faricimab for neovascular age-related macular degeneration in real clinical practice [0.03%]
法瑞西单抗治疗湿性年龄相关性黄斑变性的药物经济学分析
Jorge Ruiz-Medrano,Mariluz Puertas,María Hinojosa-Gonzalez et al.
Jorge Ruiz-Medrano et al.
Introduction: Neovascular age-related macular degeneration (nAMD) is one of the leading causes of severe vision loss among older adults. This condition impairs patients' quality of life and imposes a significant economic ...
Comments on: Use of artificial intelligence to draft a mini-HTA report on a new medical device belonging to class IIb-III [0.03%]
关于使用人工智能撰写IIb-III类新型医疗器械mini-HTA报告的评论
Erminia Caccese,Ramona Giardino,Maria Gabriella Paolì et al.
Erminia Caccese et al.
Impact of AIFA Note 100 on innovative antidiabetic prescribing eligibility in two Italian local health authorities: drug utilization and patient characteristics [0.03%]
意大利两个地方卫生局的AIFA Note 100对创新抗糖尿病药物处方资格的影响：药品使用情况和患者特征
Giacomo M Bruno,Maria Chiara Valentino,Stefano Buda et al.
Giacomo M Bruno et al.
Introduction: Type 2 diabetes mellitus (T2DM) is a common chronic disease with management, associated with cardiovascular and renal comorbidities. In January 2022, AIFA Note 100 extended prescribing authority for innovati...
Impact of Ministerial Decree 77/2022 from different stakeholders' perspectives: clinicians, pharmacists, patients, and industry [0.03%]
从不同利益相关者角度分析第77号部级法令（ ministerial decree No. 77/2022）的影响：临床医生、药剂师、患者及工业界的视角
Guido Attilio Condorelli,Martina Pipoli,Deborah Bonifacio et al.
Guido Attilio Condorelli et al.
Introduction: Assess the implications of Ministerial Decree (MD) 77/2022 in Italy, which decentralizes healthcare through proximity-based models, from the perspective of key actors involved, and discuss its relevance to s...
Comments on: Italian Medicines Agency's reform and time until pricing and reimbursement decisions: a time-to-event analysis [0.03%]
意大利药物机构改革及定价和报销决定所需时间的评论：一项事件发生时间分析
Giuseppe Traversa,Antonio Addis
Giuseppe Traversa
Author's reply to comments to: Italian Medicines Agency's reform and time until pricing and reimbursement decisions: a time-to-event analysis [0.03%]
致意大利药物管理局改革及药品定价和报销决定时间分析评论作者的回信
Gian Marco Raspolini,Bruno Federico,Mario Cesare Nurchis et al.
Gian Marco Raspolini et al.
Procedural activity and dynamics of the new Italian Scientific and Economic Committee (CSE): a one-year observational analysis [0.03%]
意大利新科学经济委员会(CSE)的程序活动和动态：一年观察分析
Entela Xoxi,Giulia Fagnocchi,Giovanni Callegaro et al.
Entela Xoxi et al.
Introduction: In January 2024, the Commissione Scientifica ed Economica (CSE) became the national body responsible for the integrated scientific and economic evaluation of medicines in Italy. This study provides the first...